<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953286</url>
  </required_header>
  <id_info>
    <org_study_id>DR210051</org_study_id>
    <nct_id>NCT04953286</nct_id>
  </id_info>
  <brief_title>Ocular Surface Metabolo-lipidomics in Lateral Amyotrophic Sclerosis</brief_title>
  <acronym>LARMOMIQUE</acronym>
  <official_title>Tear Fluid and Ocular Surface Metabolomics and Lipidomics in Lateral Amyotrophic Sclerosis: a Prospective Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS) is the most common neurodegenerative disease affecting&#xD;
      the motor neuron. Currently, there is no diagnostic test and no examination that can predict&#xD;
      the evolution of this pathology. The search for diagnostic and prognostic biomarkers is&#xD;
      therefore essential for a better understanding of the pathophysiology of ALS, which remains&#xD;
      poorly understood, and also for better clinical management. The ocular surface, made up of&#xD;
      liquid elements, tears, and cells, is an accessible anatomical-physiological entity that has&#xD;
      demonstrated its usefulness in the identification of biomarkers in neurodegenerative diseases&#xD;
      such as Parkinson's or Alzheimer's. To date, no study has explored the ocular surface as a&#xD;
      biomarker in ALS&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolome profile in tears for the diagnosis and prognosis of ALS.</measure>
    <time_frame>Baseline</time_frame>
    <description>Once the composition in metabolites (i.e. tear metabolome) is determined, statistical univariate and multivariate analyses will aim to determine if the tear metabolome can cluster ALS patients and controls and therefore can be used as a diagnosis biomarker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolome profile in intra-cellular contents for the diagnosis and prognosis of ALS.</measure>
    <time_frame>Baseline</time_frame>
    <description>Once the composition in metabolites in conjunctival cells is determined, statistical univariate and multivariate analyses will aim to determine if the tear metabome can cluster ALS patients and controls and therefore can be used as a diagnosis biomarker.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipidome profile in tears for the diagnosis and prognosis of ALS.</measure>
    <time_frame>Baseline</time_frame>
    <description>Once the composition in lipids (i.e. tear lipidome) is determined, statistical univariate and multivariate analyses will aim to determine if the tear lipidome can cluster ALS patients and controls and therefore can be used as a diagnosis biomarker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipidome profile in intra-cellular contents for the diagnosis and prognosis of ALS.</measure>
    <time_frame>Baseline</time_frame>
    <description>Once the composition in lipids in conjunctival cells is determined, statistical univariate and multivariate analyses will aim to determine if the tear lipidome can cluster ALS patients and controls and therefore can be used as a diagnosis biomarker.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of the ocular surface metabolites during ALS progression using ultra-high performance liquid chromatography coupled with mass spectrometry</measure>
    <time_frame>Baseline</time_frame>
    <description>By carrying out a longitudinal analysis in ALS cases, the modification in tear and cells metabo-lipidome will be assessed at three time-points (at diagnosis, at month 3 and 6) and will correlated with bioclinical criteria of ALS progression (i.e. % of weight loss, % of slope of progression of the ALS-FRS-r score and % of decrease in forced vital capacity). This analysis will aim to search for analytes that can predict ALS progression (i.e. prognosis biomarker).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the ocular surface lipids during ALS progression using ultra-high performance liquid chromatography coupled with mass spectrometry</measure>
    <time_frame>Baseline</time_frame>
    <description>By carrying out a longitudinal analysis in ALS cases, the modification in tear and cells metabo-lipidome will be assessed at three time-points (at diagnosis, at month 3 and 6) and will correlated with bioclinical criteria of ALS progression (i.e. % of weight loss, % of slope of progression of the ALS-FRS-r score and % of decrease in forced vital capacity). This analysis will aim to search for analytes that can predict ALS progression (i.e. prognosis biomarker).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients with Amyotrophic Lateral Sclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients without neurological disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measure of visual acuity</intervention_name>
    <description>ETDRS and Parinaud scale</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interferometry</intervention_name>
    <description>Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples of basal tears</intervention_name>
    <description>Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Central corneal sensitivity</intervention_name>
    <description>Central corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Slit lamp examination and undilated fundus</intervention_name>
    <description>Slit lamp examination and undilated fundus</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conjunctival impression</intervention_name>
    <description>Conjunctival impression with anesthetic instillation</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of the corneal innervation</intervention_name>
    <description>Contact corneal confocal microscopy</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Case group selection criteria :&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with clinically defined or probable primary ALS according to Airlie House&#xD;
             criteria(1)&#xD;
&#xD;
          -  Familial or sporadic form&#xD;
&#xD;
          -  ≥18 years of age and ≤75 years of age&#xD;
&#xD;
          -  Patient affiliated with a social security plan&#xD;
&#xD;
          -  Informed consent signed by the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Motor neuron disease mimicking ALS&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Treatment that may have a neuroprotective effect&#xD;
&#xD;
          -  Any eye drops or treatments that may interfere with tear production&#xD;
&#xD;
          -  Lens wearer&#xD;
&#xD;
          -  Eye surgery ≤3 months&#xD;
&#xD;
          -  Any ocular pathology other than ametropia, oculomotor disorder, amblyopia&#xD;
&#xD;
          -  Any general pathology other than ALS with ocular repercussions&#xD;
&#xD;
          -  Protective measure of guardianship or curators&#xD;
&#xD;
        Control group selection criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  No diagnosed neurological pathology&#xD;
&#xD;
          -  ≥18 years of age and ≤75 years of age&#xD;
&#xD;
          -  Patient affiliated with a social security plan&#xD;
&#xD;
          -  Informed consent signed by the participant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Treatment likely to have a neuroprotective effect&#xD;
&#xD;
          -  Any eye drops or treatments that may interfere with tear production&#xD;
&#xD;
          -  Lens wearer&#xD;
&#xD;
          -  Eye surgery ≤3 months&#xD;
&#xD;
          -  Any ocular pathology except ametropia, oculomotor disorder, amblyopia&#xD;
&#xD;
          -  Any general pathology with ocular repercussions&#xD;
&#xD;
          -  Protective measure of guardianship or curator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raoul Kanav KHANNA, MD</last_name>
    <phone>02.47.47.37.24</phone>
    <phone_ext>+33</phone_ext>
    <email>raoul.khanna@univ-tours.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ophthalmology Department, University Hospital of Tours, France</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raoul K Khanna, MD</last_name>
      <phone>0247472767</phone>
      <email>raoul.khanna@univ-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurology Department, University Hospital of Tours, France</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe CORCIA, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe CORCIA, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Ocular Surface</keyword>
  <keyword>Tear</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

